Israeli biotech firm Nexstage has acquired LipoQuoir and Ieyanya Pharma in a transaction that includes an FDA-approved asset and a product advancing to Phase 2 trials. The initial consideration of 10 million shekels in shares could rise by up to 16 million shekels based on development milestones. The deal shifts Nexstage’s focus toward advanced-stage assets, particularly a non-opioid treatment for post-surgical chronic pain.

Sources: Israel Hayom